Equities

Shanghai Shyndec Pharmaceutical Co Ltd

600420:SHH

Shanghai Shyndec Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.87
  • Today's Change0.44 / 4.22%
  • Shares traded12.05m
  • 1 Year change-2.77%
  • Beta--
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

  • Revenue in CNY (TTM)11.78bn
  • Net income in CNY843.91m
  • Incorporated1996
  • Employees11.61k
  • Location
    Shanghai Shyndec Pharmaceutical Co LtdNo. 378 Jianlu Road, Pudong New AreaSHANGHAI 200137ChinaCHN
  • Phone+86 2 152372865
  • Fax+86 2 158480136
  • Websitehttp://www.shyndec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Changchun BCHT Biotechnology Co1.92bn543.19m12.88bn1.24k23.673.15--6.721.321.324.649.880.41160.84591.551,543,550.0011.679.9514.1412.8189.9086.6328.3624.032.03--0.015810.5570.3012.36175.9831.3721.04--
Liaoning Cheng Da Co Ltd11.18bn17.48m12.94bn3.36k650.770.4437--1.160.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
KPC Pharmaceuticals Inc7.65bn432.35m13.55bn5.05k31.272.50--1.770.57250.572510.157.150.80212.482.621,513,702.004.635.427.769.1343.1243.685.775.701.4653.930.168835.75-6.991.6416.055.79-21.3314.87
Henan Lingrui Pharmaceutical Co., Ltd.3.43bn614.24m13.94bn2.53k22.554.72--4.061.091.096.095.210.72462.0413.841,356,471.0012.9710.6821.2716.5671.7474.4217.9014.921.26--0.012272.8010.3110.0322.0918.49-16.4739.77
Suzhou Zelgen Biopharmaceuticals Co Ltd386.57m-260.85m14.39bn867.00--9.03--37.22-1.00-1.001.496.020.16210.25943.75445,874.00-11.74-27.13-20.82-39.2092.2992.75-72.40-220.712.15--0.3842--27.83211.8139.08--41.38--
Shanghai Shyndec Pharmaceutical Co Ltd11.78bn843.91m14.58bn11.61k17.001.15--1.240.63940.63948.959.480.60693.086.611,014,487.005.754.858.508.1737.0943.009.487.031.82--0.105717.52-6.861.2910.21-0.3897-2.210.00
Jiang Zhong Pharmaceutical Co Ltd4.30bn734.24m14.63bn4.01k19.943.55--3.401.171.176.836.550.66984.3413.621,071,799.0012.3510.8218.8215.0864.0165.0218.4418.171.47--0.006182.8813.0020.1218.408.5411.4740.99
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.18bn208.25m15.65bn1.55k74.536.90--13.250.97690.97695.5410.550.37431.214.71764,598.406.695.869.157.5963.1555.4117.8717.201.0833.770.335627.5958.6932.2426.2029.9927.32--
Chongqing Taiji Industry Group Co Ltd15.40bn834.00m15.80bn12.59k18.954.08--1.031.501.5027.666.951.033.155.841,223,535.005.770.781417.832.3546.1444.035.620.84980.53156.120.539325.7610.587.88131.9963.553.8624.57
BrightGene Bio-Medical Technology Co Ltd1.21bn195.77m15.88bn1.16k82.306.54--13.080.45690.45692.875.750.24631.694.431,051,700.003.436.534.297.9354.9256.9313.9319.901.454.860.478729.3115.9423.68-15.5122.5629.13--
Data as of Jul 05 2024. Currency figures normalised to Shanghai Shyndec Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.44%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 31 Dec 202329.60m2.21%
China Merchants Fund Management Co., Ltd.as of 30 Sep 202313.59m1.01%
Monetary Authority of Macao (Investment Management)as of 30 Sep 20239.27m0.69%
CCB Principal Asset Management Co., Ltd.as of 31 Dec 20234.86m0.36%
GF Fund Management Co., Ltd.as of 31 Dec 20234.64m0.35%
The Vanguard Group, Inc.as of 31 May 20243.45m0.26%
China Southern Asset Management Co., Ltd.as of 31 Dec 20232.04m0.15%
China Asset Management Co., Ltd.as of 31 Dec 20232.02m0.15%
Tian Hong Asset Management Co., Ltd.as of 31 Dec 20231.92m0.14%
Dimensional Fund Advisors LPas of 06 Jun 20241.59m0.12%
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.